NOWDiagnostics, a subsidiary of the renowned Quest Diagnostics (NYSE: DGX), is excited to announce the successful closure of a $22.5 million funding round, aimed at further enhancing its mission to empower individuals with actionable health insights. Quest Diagnostics, widely acknowledged as a leader in the field of diagnostics, leverages the world’s largest database of clinical lab results to illuminate new pathways for disease identification and treatment. With their extensive reach, serving one in three adult Americans, the company is committed to transforming health outcomes through groundbreaking diagnostic innovations.
The newly acquired capital will be strategically invested into the development of advanced diagnostic technologies and increasing access to their already vast test menu, which boasts over 3,000 tests. This funding will also facilitate initiatives aimed at improving connectivity solutions within healthcare organizations and further streamlining processes for clinicians. Quest Diagnostics' commitment to healthcare innovation is underscored by its proficient team of approximately 47,000 employees and an impressive network of laboratories, ensuring that efficient, high-quality diagnostics are delivered to patients across the United States and beyond.
As NOWDiagnostics steps into this new chapter fueled by fresh capital, the expected initiatives will bolster their leading-edge role in cancer diagnostics and expedite advancements in esoteric laboratory services. Through this funding, NOWDiagnostics not only embarks on a journey of growth but also reinforces its commitment to inspiring healthier behaviors and improving healthcare management across the globe. For more information, visit www.questdiagnostics.com.
